A. Rakowska, L. Rudnicka, M. Olszewska, B. Bergler-Czop, J. Czuwara, L. Brzezińska-Wcisło, J. Narbutt, W. Placek, Barbara Zegarska
{"title":"斑秃。波兰皮肤病学会的诊断和治疗建议。第二部分:治疗","authors":"A. Rakowska, L. Rudnicka, M. Olszewska, B. Bergler-Czop, J. Czuwara, L. Brzezińska-Wcisło, J. Narbutt, W. Placek, Barbara Zegarska","doi":"10.5114/dr.2023.127705","DOIUrl":null,"url":null,"abstract":"The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata Scale (AAS). In mild alopecia areata, very ultra-high potency topical glucocorticoids and intralesional triamcinolone acetonide are the mainstay of treatment. In moderate to severe alopecia areata, systemic treatment is usually required. Currently, the only drug dedicated for alopecia areata, approved in Europe and the United States is baricitinib. Ritlecitinib, a JAK3/TEC inhibitor is expected to be the second approved drug for this indication in the up-coming future. Other systemic medications used in alopecia areata also include glucocorticoids, cyclosporine, and methotrexate. Contact immunotherapy may be considered. In alopecia areata, long-maintenance treatment is of substantial significance.","PeriodicalId":34880,"journal":{"name":"Clinical Dermatology Review","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Alopecia areata. Diagnostic and therapeutic recommendations\\nof the Polish Society of Dermatology. Part 2: Treatment\",\"authors\":\"A. Rakowska, L. Rudnicka, M. Olszewska, B. Bergler-Czop, J. Czuwara, L. Brzezińska-Wcisło, J. Narbutt, W. Placek, Barbara Zegarska\",\"doi\":\"10.5114/dr.2023.127705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata Scale (AAS). In mild alopecia areata, very ultra-high potency topical glucocorticoids and intralesional triamcinolone acetonide are the mainstay of treatment. In moderate to severe alopecia areata, systemic treatment is usually required. Currently, the only drug dedicated for alopecia areata, approved in Europe and the United States is baricitinib. Ritlecitinib, a JAK3/TEC inhibitor is expected to be the second approved drug for this indication in the up-coming future. Other systemic medications used in alopecia areata also include glucocorticoids, cyclosporine, and methotrexate. Contact immunotherapy may be considered. In alopecia areata, long-maintenance treatment is of substantial significance.\",\"PeriodicalId\":34880,\"journal\":{\"name\":\"Clinical Dermatology Review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Dermatology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/dr.2023.127705\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Dermatology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/dr.2023.127705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment
The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata Scale (AAS). In mild alopecia areata, very ultra-high potency topical glucocorticoids and intralesional triamcinolone acetonide are the mainstay of treatment. In moderate to severe alopecia areata, systemic treatment is usually required. Currently, the only drug dedicated for alopecia areata, approved in Europe and the United States is baricitinib. Ritlecitinib, a JAK3/TEC inhibitor is expected to be the second approved drug for this indication in the up-coming future. Other systemic medications used in alopecia areata also include glucocorticoids, cyclosporine, and methotrexate. Contact immunotherapy may be considered. In alopecia areata, long-maintenance treatment is of substantial significance.